Given the promising preclinical data on TERN-501's potential in the weight-loss market, combined with positive analyst sentiment suggesting significant upside potential, I am confident that Terns Pharmaceuticals (TERN) is well-positioned for growth in the near term, justifying my purchase of its stock.